This week we’ll be at the RNA Targeted Drug Discovery Summit in Boston. CSO Domi Stickens will present on our RNA-targeted small molecule (rSM) drug program for myotonic dystrophy type 1 (DM1), and Founder & CSO Emerita Jennifer Petter shares her expertise on two panels.
#ArrakeensInAction #BioSky

Last week, we wore green for International #myotonicDystrophyAwareness Day (9/15) to raise awareness of the most common form of adult muscular dystrophy. We're developing an RNA-targeted small molecule drug program to treat myotonic dystrophy type 1 (DM1).
#myotonicDystrophy

The Arrakis team gathered to volunteer at Waltham Fields Community Farm, helping with weeding and preparing their fall harvests. We’re glad to support the Farm, its educational programs, and the food it produces for the Waltham community.

#ArrakeensInAction

To celebrate #RNADay at Arrakis, we constructed our own ‘Arrakis RNA’ made with RNA codons that translate into amino acids that represent us, whether it be one of our initials or our favorite letter, and what we can create as a team!

#ExpeditionRNA #WeAreArrakeen

Last week we joined Xilio Therapeutics and Q32 Bio to celebrate #PrideMonth with our Waltham Biotech Pride Mix & Mingle, and we collected donations of essential items for The Waltham House LGBTQ+ youth group home.
Learn more: www.thehome.org/programs/wal...
#ArrakeensInAction

Two Arrakeens are sharing their expertise at the 5th Annual Induced Proximity-Based Drug Discovery Summit in San Diego this week. Craig presents on our work targeting RNA, and Aaron leads a workshop on AI-driven co-folding. #ArrakeensInAction